Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
309
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Collin K. China Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-2819-4041View further author information
ORCID Icon,
Maria A. Rodrigueza Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Yun Qingb Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Lei Fengb Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Felipe Samaniegoa Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Preetesh Jaina Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Mansoor Noorania Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Nathan H. Fowlera Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-9494-1877View further author information
ORCID Icon,
Luis E. Fayada Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jason R. Westina Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sattva S. Neelapua Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Frederick B. Hagemeistera Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Christopher R. Flowersa Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Loretta J. Nastoupila Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 2985-2989 | Received 19 Jun 2020, Accepted 25 Jun 2020, Published online: 06 Jul 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Authorship contributions

CKC and LJN: Designed the study.

CKC, PJ and MN: Collected and assembled the data.

CKC, YQ and LF: Analyzed and interpreted the data.

CKC, MR, FS, NF, YQ, LF, JW, SSN, FBH, CF, LJN: Wrote the manuscript.

All authors gave final approval for the manuscript.

MR, FS, NF, LF, JW, SSN, FBH, CF, LJN: Provided study materials and patients.

Disclosure statement

CKC, MR, YQ, LF, FS, PJ, MN, LF, FBH: No conflicts of interest.

NF: received research support from Celgene, Roche, Janssen, TG Therapeutics and AbbVie; served as consultant and advisory board member for Celgene, Roche, Janssen, TG therapeutics and AbbVie.

JW: has received research support from Novartis, Celgene, Janssen, Kite/Gilead, Unum, Genentech, Curis and 47 Inc; served as consultant and advisory board member for Novartis, Celgene, Juno, Janssen, Kite/Gilead, MorphoSys, Genentech and Curis.

SSN: has received research support from Kite/Gilead, Cellectis, Poseida, Merck, Acerta, Karus, BMS, Unum Therapeutics, Allogene, and Precision Biosciences; served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, Merck, Precision Biosciences, Cell Medica, Incyte, Allogene, Calibr, and Legend Biotech; has patents related to cell therapy.

CF: has received research support from AbbVie, Acerta Pharma, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Millenium/Takeda, National Institutes of Health, Onyx Pharmaceuticals, Pharmacyclics and Spectrum Pharmaceuticals; served as consultant and advisory board member for Spectrum Pharmaceuticals, Celgene, Optum Rx, Seattle Genetics, Kite/Gilead and Bayer.

LN: has received research support from TG Therapeutics, Janssen, Genentech and Celgene; has served as consultant and advisory board member for TG Therapeutics, Novartis, Janssen, Spectrum Pharmaceuticals, Kite/Gilead, Genentech, Bayer and Celgene.

Additional information

Funding

This work was supported in part by the Cancer Center Support Grant (CCSG).

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.